美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

230.98

+2.841.24%

盘后：229.75-1.0150-0.44%17:21 EDT

成交量：51.99万

成交额：1.20亿

市值：248.81亿

市盈率：-37.72

高：234.15

开：229.30

低：227.40

收：228.14

数据加载中...

总览公司新闻公告

百济神州超越恒瑞医药，成为新一代“药王”

Ofweek维科网

百济神州遭减持3200万股！陪跑8轮融资的高瓴为何在“要赚钱”的时刻撤退

21世纪经济报道

百济神州股东HHLR Fund减持超1% 持股比例降至6.66%

百济神州，正在走安进曾经的路

Ofweek维科网

百济神州年内股价大幅上涨后，遭高瓴减持3224万股

百济神州(06160)因购股权获行使而发行100.76万股

百济神州授出购股权及受限制股份单位

百济神州2024财年实现净利润-6.45亿美元，同比增加26.87%

百济神州(06160)授出购股权及受限制股份单位

百济神州(06160.HK)授出合共3.26万股受限制股份单位

海通国际：首予百济神州(06160)“优于大市”评级目标价182.35港元

DeepSeek拆解：百济神州商业模式。

百济神州(06160)双抗癌症1类新药注射用BGB-B455申报临床

百济神州深陷亏损泥潭 2025年乐观预期增长能否实现？

富时中国A50指数将纳入寒武纪、中国联通、国泰君安

百济神州启示录：真正的创新价值终将穿越周期

【百济神州：百泽安在美国获批用于晚期食管鳞状细胞癌联合化疗的一线治疗】3月4日，百济神州宣布，美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者，以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。

美股异动 | 百济神州(ONC.US)盘前涨逾3% 替雷利珠单抗在美获批新适应症

百济神州回购253万股回购均价为0.5美元

百济神州：经营利润转正维持“买入”评级

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ONC/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":230.98,"timestamp":1744920000000,"preClose":228.14,"halted":0,"volume":519865,"hourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"delay":0,"floatShares":79387510,"shares":107719405,"eps":-6.124009,"marketStatus":"休市中","change":2.84,"latestTime":"04-17 16:00:00 EDT","open":229.3,"high":234.15,"low":227.3961,"amount":119885584.17555,"amplitude":0.029604,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.124009,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":228.14,"preHourTrading":{"tag":"盘前","latestPrice":233.81,"preClose":228.14,"latestTime":"08:41 EDT","volume":73,"amount":17065.739250000002,"timestamp":1744893686762},"postHourTrading":{"tag":"盘后","latestPrice":229.75,"preClose":230.765,"latestTime":"17:21 EDT","volume":54100,"amount":12495855.13,"timestamp":1744924915084},"volumeRatio":0.7116059393545304,"impliedVol":0.529,"impliedVolPercentile":0.8767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":79387510,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":0.7116059393545304,"shares":107719405,"dividePrice":0,"high":234.15,"amplitude":0.029604,"preClose":228.14,"low":227.3961,"week52Low":126.9681,"pbRate":"7.47","psRate":"6.53","week52High":287.88,"institutionHeld":0,"latestPrice":230.98,"eps":-6.124009,"divideRate":0,"volume":519865,"delay":0,"ttmEps":-6.124009,"open":229.3,"prevYearClose":184.71,"prevWeekClose":230.36,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":208.31,"twentyDayClose":262.59,"sixtyDayClose":222.22,"earningDate":1746547200000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517171473","title":"百济神州超越恒瑞医药，成为新一代“药王”","url":"https://stock-news.laohu8.com/highlight/detail?id=2517171473","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517171473?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 16:02","pubTimestamp":1741334538,"startTime":"0","endTime":"0","summary":"百济神州市值超越恒瑞医药，成为国内当之无愧的“医药一哥”。百济神州的成长性、研发投入远超恒瑞医药，且规模已经迎头赶上，从这一点来看无愧于新一代“药王”的美誉，不过，百济神州高度分散的股权、亏损问题仍需引起重视，这一点是比不上恒瑞医药的。投资者喜欢投资高成长性的企业，显然百济神州符合该要求，这也是其备受青睐，市值能够反超恒瑞医药的关键。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307160320989f926e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307160320989f926e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK4139"],"gpt_icon":0},{"id":"2517124090","title":"百济神州遭减持3200万股！陪跑8轮融资的高瓴为何在“要赚钱”的时刻撤退","url":"https://stock-news.laohu8.com/highlight/detail?id=2517124090","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517124090?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 13:41","pubTimestamp":1741326104,"startTime":"0","endTime":"0","summary":"【百济神州遭减持3200万股！陪跑8轮融资的高瓴为何在“要赚钱”的时刻撤退】根据2月15日，HHLR Advisors公布的截至2024年四季度末的美股持仓情况，基金相比去年三季度减少了3只持仓标的，持仓市值减少30%至28.87亿美元。其中，高瓴减持百济神州173.25万股，较去年三季度持股数减少了26.51%，虽然从市值看，截至去年四季度末百济神州仍是高瓴第一大重仓股，但在投资组合中的占比从上季度的18.13%降至11.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503073339657822.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503073339657822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","06160","BK1500","LU2328871848.SGD","BK1583","BK1161","BK4139","LU0307460666.USD","ONC","BK1588","LU0588546209.SGD"],"gpt_icon":0},{"id":"2517126147","title":"百济神州股东HHLR Fund减持超1% 持股比例降至6.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517126147","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517126147?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 12:29","pubTimestamp":1741321763,"startTime":"0","endTime":"0","summary":"3月6日，百济神州（688235）发布公告称，公司持股5%以上股东HHLRFund,L.P.及其联属实体于2025年3月3日至4日通过大宗交易方式合计减持公司境外流通股3224万股，持股比例由8.97%降至6.66%，权益变动比例达2.31%。本次减持不触及要约收购，公司仍维持无控股股东及实际控制人状态。HHLR正是高瓴旗下独立的、专注于二级市场投资的基金管理平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503073339606344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","ONC","LU0307460666.USD","BK1583","LU0588546209.SGD","LU2328871848.SGD","BK1500","BK1588","06160","LU1969619763.USD","BK1161"],"gpt_icon":0},{"id":"2517472731","title":"百济神州，正在走安进曾经的路","url":"https://stock-news.laohu8.com/highlight/detail?id=2517472731","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517472731?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 10:57","pubTimestamp":1741316274,"startTime":"0","endTime":"0","summary":"随着百济神州2024年财报的披露，其再次向市场深化了“创新药一哥”的定位。无论是市值规模，还是产品成熟度，百济神州显然与安进都不是一个等级的对手，简单静态对比并不能得出什么有效结论。如果以此视角推测，虽然不能说百济神州估值过高，但也应警惕如当年安进估值回落盘整的风险。如果说百济神州正在走安进曾经的路，那么长达十二年的潜在瓶颈期才是最考验投资者认知的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307105805989f4f22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307105805989f4f22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0588546209.SGD","LU1969619763.USD","BK1588","BK1500","LU2328871848.SGD","BK1583","LU0307460666.USD","ONC","06160","BK1161","688235"],"gpt_icon":0},{"id":"2517445631","title":"百济神州年内股价大幅上涨后，遭高瓴减持3224万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517445631","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517445631?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 10:21","pubTimestamp":1741314100,"startTime":"0","endTime":"0","summary":"今年以来，截至3月6日，百济神州美股、H股、A股三地股价涨幅均超过39%，而重要股东的减持也随之而来。2023年6月8日至2024年12月2日期间，高瓴曾通过集中竞价和大宗交易方式合计减持百济神州境外流通股股份2199.73万股。泽布替尼正是百济神州的“10亿美元分子”，这是公司自主研发的一款BTK抑制剂，2024年，这款产品销售额达到188.59亿元，再创新高，占公司营业收入近七成。百济神州方面亦表示，公司开发的BTK降解剂充满期待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307102216a2634972&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307102216a2634972&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","688235","06160","ONC"],"gpt_icon":0},{"id":"2517104491","title":"百济神州(06160)因购股权获行使而发行100.76万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2517104491","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517104491?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 08:22","pubTimestamp":1741306945,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，因一名董事于2025年3月6日行使购股权而发行普通股100.76万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","ONC","LU2328871848.SGD","LU0307460666.USD","BK1161","688235","LU0588546209.SGD","LU1969619763.USD","BK1583","BK0239","BK1588","BK1500","06160"],"gpt_icon":0},{"id":"2517831110","title":"百济神州授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517831110","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517831110?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 08:12","pubTimestamp":1741306320,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予一名承授人可认购合共1100股美国存托股份的购股权。\n　　于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予151名承授人合共3.26万股美国存托股份受限制股份单位。该等受限制股份单位相当于42.35万股股份，约占本公告之日公司发行股份总数的0.03%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-07/doc-inenuqsp7165037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","LU1969619763.USD","LU0588546209.SGD","BK1161","06160","BK1588","BK1583","LU2328871848.SGD","688235","BK0239","LU0307460666.USD","BK4139","BK1500"],"gpt_icon":0},{"id":"2517916251","title":"百济神州2024财年实现净利润-6.45亿美元，同比增加26.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517916251?lang=zh_cn&edition=fundamental","pubTime":"2025-03-07 00:00","pubTimestamp":1741276839,"startTime":"0","endTime":"0","summary":"3月7日，百济神州公布财报，公告显示公司2024财年净利润为-6.45亿美元，同比增加26.87%；其中营业收入为38.10亿美元，同比增加54.94%，每股基本收益为-6.12美元。从资产负债表来看，百济神州总负债25.63亿美元，其中短期债务8.69亿美元，资产负债比为2.32，流动比率为1.81。机构评级：截至2025年3月7日，当前有28家机构对百济神州目标价做出预测，其中目标均价为333.10美元，其中最低目标价为207.00美元，最高目标价为486.31美元。百济神州有自己的团队进行全球临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000044a262a5d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000044a262a5d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC"],"gpt_icon":0},{"id":"2517853165","title":"百济神州(06160)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517853165","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517853165?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:15","pubTimestamp":1741270511,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予一名承授人可认购合共1100股美国存托股份的购股权。于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款授予151名承授人合共3.26万股美国存托股份受限制股份单位。该等受限制股份单位相当于42.35万股股份，约占本公告之日公司发行股份总数的0.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4139","LU0588546209.SGD","LU1969619763.USD","BK1588","BK1500","LU2328871848.SGD","BK1583","LU0307460666.USD","ONC","06160","BK1161","688235"],"gpt_icon":0},{"id":"2517163194","title":"百济神州(06160.HK)授出合共3.26万股受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163194","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163194?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 22:12","pubTimestamp":1741270358,"startTime":"0","endTime":"0","summary":"格隆汇3月6日丨百济神州(06160.HK)公告，于2025年3月3日，董事会薪酬委员会根据2016期权及激励计划的条款向一名承授人授出可认购合共1,100股美国存托股份的购股权并向一百五十一名承授人授出涉及合共32,579股美国存托股份的受限制股份单位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06221248575249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688235","ONC","LU2328871848.SGD","BK1500","BK1588","06160","BK1583","LU0588546209.SGD","LU1969619763.USD","BK4139","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2517313483","title":"海通国际：首予百济神州(06160)“优于大市”评级 目标价182.35港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517313483","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517313483?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 17:21","pubTimestamp":1741252896,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海通国际发布研报称，首次覆盖百济神州，给予“优于大市”评级。使用现金流折现模型及FY25-FY34的现金流进行估值，基于WACC9%，永续增长率4.0%，对应目标价182.35元港元。海通国际主要观点如下：百济神州是中国创新药出海龙头，其生物药创新研发能力和全球商业化能力位居中国前列百济神州成立于2010年，是一家全球肿瘤治疗创新公司，聚焦血液肿瘤、实体瘤等领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2517902140","title":"DeepSeek拆解：百济神州商业模式。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517902140","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517902140?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 12:15","pubTimestamp":1741234554,"startTime":"0","endTime":"0","summary":"百济神州科创板市值以冲破3000亿元超越恒瑞医药，一举成为A股市值最高的药企。以下内容由人工大模型DeepSeek生成，仅供参考，或存在机器幻觉，请注意甄别。例如，BTK抑制剂赛道美股平均PS为8-10倍，而百济神州凭借更高增速获得溢价。百济神州的商业模式实质是 “21世纪的技术殖民” ——利用发展中国家的低成本要素完成原始积累，再通过发达国家制度优势实现价值捕获。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130130abeac3af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306130130abeac3af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2517905413","title":"百济神州(06160)双抗癌症1类新药注射用BGB-B455申报临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2517905413","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517905413?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 10:52","pubTimestamp":1741229535,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国国家药监局药品审评中心官网近日公示，百济神州的1类新药注射用BGB-B455临床试验申请获得受理。本次为该产品首次在中国申报IND。由于其在肿瘤中的表达优于正常组织，claudin 6 是一种理想的靶向肿瘤抗原。公开资料显示，BGB-B455是一种双特异性抗体，其靶向肿瘤细胞上的CLDN6和T细胞上的CD3受体。它可能以更耐受的方式提供CLDN6依赖性抗肿瘤免疫应答，而不会产生过度的全身毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU1969619763.USD","LU0588546209.SGD","BK1161","06160","BK1588","BGB","BK1583","688235","LU2328871848.SGD","BK0239","LU0307460666.USD","BK4139","BK1500"],"gpt_icon":0},{"id":"2517976453","title":"百济神州深陷亏损泥潭 2025年乐观预期增长能否实现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976453","media":"电鳗快报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976453?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 08:17","pubTimestamp":1741220220,"startTime":"0","endTime":"0","summary":"在医药创新领域，百济神州作为一家致力于发现和开发创新性疗法的全球肿瘤创新公司，近年来一直备受瞩目。自2017年至2024年，百济神州在过去的八年里累计亏损高达591亿元。值得注意的是，虽然百济神州的营收呈现增长态势，但其净利润仍处于巨额亏损阶段。未来，随着新药的陆续上市和市场份额的不断扩大，百济神州有望逐步改善其财务状况，实现可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306081908963b5f18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306081908963b5f18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","BK1583","BK1161","LU0588546209.SGD","LU0307460666.USD","LU2328871848.SGD","ONC","LU1969619763.USD","BK1588","BK1500"],"gpt_icon":0},{"id":"2517486921","title":"富时中国A50指数将纳入寒武纪、中国联通、国泰君安","url":"https://stock-news.laohu8.com/highlight/detail?id=2517486921","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517486921?lang=zh_cn&edition=fundamental","pubTime":"2025-03-06 05:16","pubTimestamp":1741209363,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["03189","XX25.UK","ONC","003816","BK0167","BK0017","IE00B5MMRT66.SGD","688235","MNQmain","000063","BK0082","BK1536","BK1133","000568","BK1588","IWN","RWM","IE0005HP3H50.USD","LU0650527681.SGD","02611","00762","00763","BK0276","IWO","LU2213484517.USD","LU0821914370.USD","TWM","UWM","601211","IWM","600887","BK0164","83189","688256","300124","600104","LU1820825898.SGD","LU1328615791.USD","601127","600050","BK1529","LU2778985437.USD","SRTY","BK0028","159593","BK0020","TNA","MRTYmain","06160","TZA"],"gpt_icon":0},{"id":"2517679499","title":"百济神州启示录：真正的创新价值终将穿越周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2517679499","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517679499?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 16:17","pubTimestamp":1741162620,"startTime":"0","endTime":"0","summary":"在创新药行业经历周期调整的背景下，百济神州交出了一份令市场振奋的成绩单。百济神州的国际化战略是其最显著的核心竞争力之一。根据最新的NCCN指南更新，CLL/SLL的治疗目前主要依赖于分子靶向药物，特别是新一代BTK抑制剂和BCL-2抑制剂。从“Biotech”到“Biopharma”的蜕变，百济神州的故事是“中国创新”走向全球的缩影。当市场还在争论创新药企何时盈利时，国产创新药企已用扎实的临床数据和出色的商业化成果给出答案，真正的创新价值终将穿越周期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305161826989cd4ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305161826989cd4ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK0239","06160","688235"],"gpt_icon":0},{"id":"2517802379","title":"【百济神州：百泽安在美国获批用于晚期食管鳞状细胞癌联合化疗的一线治疗】3月4日，百济神州宣布，美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者，以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517802379","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517802379?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 07:10","pubTimestamp":1741129814,"startTime":"0","endTime":"0","summary":"3月4日，百济神州宣布，美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者，以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05071048524623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","ONC","BK1500","BK4139","BK0239","BK1161","BK1588","BK4023","LU1169589451.USD","LU1169590202.USD","LU0588546209.SGD","LU2328871848.SGD","BK1583","PD","LU1969619763.USD","06160","688235"],"gpt_icon":0},{"id":"2516672138","title":"美股异动 | 百济神州(ONC.US)盘前涨逾3% 替雷利珠单抗在美获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2516672138","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516672138?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 22:29","pubTimestamp":1741098561,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，百济神州(ONC.US)美股盘前涨逾3%，报253.98美元。消息面上，3月4日，百济神州宣布，美国FDA已批准百泽安®(替雷利珠单抗)联合含铂化疗用于肿瘤表达PD-L1(≥1)的不可切除或转移性食管鳞状细胞癌(ESCC)成人患者一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","ONC","LU2328871848.SGD","LU0307460666.USD","BK1161","688235","LU0588546209.SGD","LU1969619763.USD","BK1583","BK0239","BK1588","BK1500","06160"],"gpt_icon":0},{"id":"2516629227","title":"百济神州回购253万股 回购均价为0.5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629227","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516629227?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 18:14","pubTimestamp":1741083252,"startTime":"0","endTime":"0","summary":"3月4日，百济神州（688235/06160/BGNE）发布公告，2025年3月3日，公司因一名董事行使购股权回购股份253万股，回购均价为0.5美元。2024年前三季度，百济神州实现收入191.36亿元，归母净利润-36.87亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336135736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","LU0588546209.SGD","LU1969619763.USD","BK1588","BK1500","LU2328871848.SGD","BK1583","LU0307460666.USD","ONC","06160","BK1161"],"gpt_icon":0},{"id":"2516455116","title":"百济神州：经营利润转正 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2516455116","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516455116?lang=zh_cn&edition=fundamental","pubTime":"2025-03-04 15:12","pubTimestamp":1741072365,"startTime":"0","endTime":"0","summary":"交银国际报告称，百济神州核心产品放量迅速，泽布替尼美国新患份额跃居首位。去年第四季销售收入 11.18 亿美元，同比增长 77%，其中泽布替尼 8.28 亿美元，环比增 20%，美国销售 6.16 亿美元，环比增 22%。全年经调整经营利润转正至 4536 万美元。交银国际上调百济神州 2025 和 2026 年收入预测，分别至 51 亿和 62 亿美元、泽布替尼全球高峰销售预测至 69 亿美元，并上调百济神州美股、港股及 A 股目标价，维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304152325989b2461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304152325989b2461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-07","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1746604800000,"name":null,"time":"盘前","dateTimestamp":1746590400000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-17","current":-38.113584,"percent":0.422535,"low":-46.072488,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"high":-22.805663,"avg":-34.842528,"sd":7.324243,"marketCap":24575105056},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056}],"updateTime":1745134919326}}}